XORTX Therapeutics (XRTX) Interest & Investment Income (2022 - 2026)
XORTX Therapeutics' (XRTX) quarterly Interest & Investment Income came in at $1635.0 in Q1 2026, down 91.12% YoY from $18421.0 in Q1 2025, and down 58.31% on a QoQ basis from $3922.0 in Q4 2025.
XORTX Therapeutics (XRTX) Interest & Investment Income (2022 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 5 years of Interest & Investment Income data on file, last reported at $1635.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 91.12% year-over-year to $1635.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25084.0 (down 76.93% YoY) and the FY2025 annual result came in at $41870.0, down 65.65% from the prior year.
- Interest & Investment Income eased to $1635.0 in Q1 2026, from $3922.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $92782.9 in Q4 2023 to a low of -$54577.3 in Q2 2023.
- A 5-year average of $6271.1 and a median of $7201.0 in 2025 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 334.46% in 2023, down 491.5% in 2023.
- Tracing XRTX's Interest & Investment Income over 5 years: stood at -$39572.7 in 2022, then surged by 334.46% to $92782.9 in 2023, then tumbled by 72.7% to $25331.0 in 2024, then slumped by 84.52% to $3922.0 in 2025, then slumped by 58.31% to $1635.0 in 2026.
- The last three Interest & Investment Income figures came in at $1635.0 (Q1 2026), $3922.0 (Q4 2025), and $7201.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 1,635.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,635.00 |
| Dec 31, 2025 | 3,922.00 |
| Sep 30, 2025 | 7,201.00 |
| Jun 30, 2025 | 12,326.00 |
| Mar 31, 2025 | 18,421.00 |
| Dec 31, 2024 | 25,331.00 |
| Sep 30, 2024 | 29,023.00 |
| Jun 30, 2024 | 35,952.00 |
| Dec 31, 2023 | 92,782.86 |
| Sep 30, 2023 | 47,451.62 |
| Jun 30, 2023 | -54,577.30 |
| Mar 31, 2023 | -49,413.20 |
| Dec 31, 2022 | -39,572.74 |
| Sep 30, 2022 | -27,188.82 |
| Jun 30, 2022 | -9,226.98 |